Harbor Capital Advisors Inc. Has $1.31 Million Stake in Solventum Corporation $SOLV

Harbor Capital Advisors Inc. lowered its position in Solventum Corporation (NYSE:SOLV) by 72.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,975 shares of the company’s stock after selling 46,933 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Solventum were worth $1,312,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of SOLV. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Solventum by 0.7% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after purchasing an additional 140 shares during the period. CHICAGO TRUST Co NA increased its position in Solventum by 3.0% during the third quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock worth $379,000 after buying an additional 150 shares during the last quarter. Applied Finance Capital Management LLC lifted its position in shares of Solventum by 3.8% in the second quarter. Applied Finance Capital Management LLC now owns 4,428 shares of the company’s stock valued at $336,000 after buying an additional 162 shares during the last quarter. Lazard Asset Management LLC lifted its position in shares of Solventum by 1.4% in the second quarter. Lazard Asset Management LLC now owns 11,605 shares of the company’s stock valued at $880,000 after buying an additional 163 shares during the last quarter. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Solventum by 0.7% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 24,295 shares of the company’s stock worth $1,843,000 after acquiring an additional 176 shares during the period.

Analyst Ratings Changes

SOLV has been the subject of several research reports. Wells Fargo & Company raised their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a report on Monday, September 15th. BTIG Research upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Tuesday, December 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $87.00.

Solventum Price Performance

NYSE:SOLV opened at $80.45 on Friday. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $88.20. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The firm’s 50-day simple moving average is $77.73 and its 200 day simple moving average is $74.87. The firm has a market cap of $13.95 billion, a price-to-earnings ratio of 9.27, a P/E/G ratio of 8.46 and a beta of 0.26.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same quarter in the prior year, the business posted $1.64 EPS. The business’s revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, sell-side analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum announced that its board has initiated a stock repurchase program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 7.5% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.